Casdin Capital 13F holdings, Q4 2018
Holdings as of December 31, 2018 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 31 US equity positions worth $584.5m in its Q4 2018 13F filing. The largest position was LOXO ONCOLOGY INC at 8.6% of the reported book, followed by MYOKARDIA INC and 2655787D. Against the Q3 2018 filing, it opened 3 new positions, added to 9 and reduced 8 among the top 31 holdings.
What did Casdin Capital own in Q4 2018? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2018 |
|---|---|---|---|---|---|---|---|
| 1 | LOXO ONCOLOGY INC | 8.6% | $50.4m | 360,000 | 0% | held | |
| 2 | MYOKARDIA INC | 6.6% | $38.6m | 790,000 | -2% | reduced | |
| 3 | 2655787D BLUEPRINT MEDICINES CORP | 5.9% | $34.5m | 640,000 | -15% | reduced | |
| 4 | CDXS CODEXIS INC | Healthcare | 5.8% | $33.8m | 2,025,000 | 0% | held |
| 5 | SPARK THERAPEUTICS INC | 5.6% | $32.9m | 840,000 | 24% | added | |
| 6 | BLUEBIRD BIO INC | 5.6% | $32.7m | 330,000 | 28% | added | |
| 7 | FATE FATE THERAPEUTICS INC | Healthcare | 5.6% | $32.7m | 2,550,000 | 0% | held |
| 8 | SG7 SAGE THERAPEUTICS INC | 5.1% | $29.9m | 312,000 | 0% | held | |
| 9 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 5.0% | $29.2m | 2,428,571 | 0% | held |
| 10 | INVITAE CORP | 4.5% | $26.5m | 2,400,000 | 0% | held | |
| 11 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 4.4% | $25.9m | 355,000 | 31% | added |
| 12 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 3.5% | $20.5m | 445,000 | -23% | reduced |
| 13 | GNMK GENMARK DIAGNOSTICS INC | 3.2% | $18.5m | 3,815,000 | 9% | added | |
| 14 | AUDENTES THERAPEUTICS INC | 3.1% | $18.3m | 860,000 | 38% | added | |
| 15 | ILMN ILLUMINA INC | Healthcare | 3.1% | $18.0m | 60,000 | -16% | reduced |
| 16 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 2.8% | $16.4m | 150,000 | 275% | added |
| 17 | MAGENTA THERAPEUTICS INC | 2.6% | $15.1m | 2,643,317 | 17% | added | |
| 18 | GLOBAL BLOOD THERAPEUTICS IN | 2.5% | $14.4m | 350,000 | -20% | reduced | |
| 19 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 2.1% | $12.4m | 1,080,000 | -46% | reduced |
| 20 | 2JQ GRITSTONE ONCOLOGY INC | 1.9% | $11.1m | 720,586 | 0% | held | |
| 21 | EVH EVOLENT HEALTH INC | Healthcare | 1.9% | $11.0m | 550,000 | 0% | held |
| 22 | EDIT EDITAS MEDICINE INC | Healthcare | 1.9% | $10.9m | 480,000 | 4% | added |
| 23 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 1.8% | $10.6m | 1,128,075 | -1% | reduced |
| 24 | ONC BEIGENE LTD | Healthcare | 1.7% | $9.8m | 70,000 | 0% | held |
| 25 | HOMOLOGY MEDICINES INC | 1.3% | $7.8m | 350,000 | 0% | held | |
| 26 | CNST CONSTELLATION PHARMCETICLS I | 1.1% | $6.2m | 1,556,998 | 18% | added | |
| 27 | IBB ISHARES TR | 1.0% | $5.8m | 60,000 | – | new | |
| 28 | CDNA CAREDX INC | Healthcare | 0.9% | $5.0m | 200,000 | 0% | held |
| 29 | DNLI DENALI THERAPEUTICS INC | Healthcare | 0.4% | $2.1m | 100,000 | – | new |
| 30 | QUOTIENT LTD | 0.3% | $2.0m | 325,000 | – | new | |
| 31 | NEON THERAPEUTICS INC | 0.2% | $1.3m | 263,344 | -22% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.